CXBS (Corix Bioscience) Net Debt Paydown Yield % : 0.00% (As of Jul. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Corix Bioscience Net Debt Paydown Yield %?

Corix Bioscience CXBS -99.00% Net Debt Paydown Yield % is 0.00% as of Jul. 14, 2026.

Net Debt Paydown Yield % is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. It is a measure of a company's willingness and ability to reduce its debt. As of today, Corix Bioscience's Net Debt Paydown Yield % was 0.00%.


Corix Bioscience  (OTCPK:CXBS) Net Debt Paydown Yield % Explanation

Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced. In other words, it is a measure of the willingness and ability of a firm's management to pay down debt. Companies that have high debt paydown yields indicate that they are more aggressive with paying down debt.

In the calculation of Net Debt Paydown Yield %, we use the reductions of TTM average total debt one-year-ago and TTM average total debt at present, divided by its Market Cap.

We calculating the TTM average debt by adding up the total debt, calculated by the sum of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation, in the trailing twelve months(TTM) divided by the counts of the total debt, accoring to the company's report frequency.


Corix Bioscience Net Debt Paydown Yield % Related Terms


Corix Bioscience Net Debt Paydown Yield % Historical Data

* Premium members only.

The historical data trend for Corix Bioscience's Net Debt Paydown Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Corix Bioscience Net Debt Paydown Yield % Chart

Corix Bioscience Annual Data
Trend Jan09 Jan10 Jan11 Jan12 Jan13 Jan14 Jan15 Dec16
Net Debt Paydown Yield %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Corix Bioscience Quarterly Data
Oct12 Jan13 Apr13 Jul13 Oct13 Jan14 Apr14 Jul14 Oct14 Jan15 Apr15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17
Net Debt Paydown Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

CXBS vs BKIT, YBAO, HSTI: Net Debt Paydown Yield % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Corix Bioscience's Net Debt Paydown Yield %, along with its competitors' market caps and Net Debt Paydown Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Corix Bioscience Net Debt Paydown Yield % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Corix Bioscience's Net Debt Paydown Yield % distribution charts can be found below:

* The bar in red indicates where Corix Bioscience's Net Debt Paydown Yield % falls into.



Corix Bioscience Net Debt Paydown Yield % Calculation

Corix Bioscience's Net Debt Paydown Yield % for the quarter that ended in Sep. 2017 is calculated as:

Net Debt Paydown Yield %
=( TTM Average Debt   (1-Year Ago))-TTM Average Debt )/Market Cap
=( 4.74-1.74 )/20.653
=14.53 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Net Debt Paydown Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.

What does a Net Debt Paydown Yield % of 0.00% mean?
Corix Bioscience (CXBS) has a Net Debt Paydown Yield % of 0.00% as of Jul. 14, 2026. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Corix Bioscience and its competitors.
Is Corix Bioscience's Net Debt Paydown Yield % too high?
Corix Bioscience's current Net Debt Paydown Yield % is 0.00%.
How does Corix Bioscience's Net Debt Paydown Yield % compare to BKIT and YBAO?
Corix Bioscience's Net Debt Paydown Yield % of 0.00% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Debt Paydown Yield % for a Drug Manufacturers company?
A good Net Debt Paydown Yield % depends on the Drug Manufacturers industry context. However, Net Debt Paydown Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Debt Paydown Yield % mean?
A high Net Debt Paydown Yield % can signal that a stock is expensive relative to its fundamentals. Net Debt Paydown Yield is a metric that evaluates the total amount of debt a company has paid in relation to its market capitalization. This metric provides insight into a company's willingness and ability to reduce its debt using free cash flow. View historical data on Corix Bioscience and its competitors. Corix Bioscience's current Net Debt Paydown Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corix Bioscience stock overvalued right now?
Corix Bioscience (CXBS) has a current Net Debt Paydown Yield % of 0.00%. The current Net Debt Paydown Yield % is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Debt Paydown Yield % calculated?
Net Debt Paydown Yield % is calculated from a company's financial statements. For Corix Bioscience (CXBS), the current Net Debt Paydown Yield % is 0.00% as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Corix Bioscience Business Description

Address 18662 MaCaurther Boulevard, Suite 200, Irvine, CA, USA, 85085
Corix Bioscience Inc is a United States-based research and development firm of cannabidiol (CBD) products and treatments. It is engaged in the business of producing organic CBD oil used for medical applications and treatments. In addition, the group is also focused on the production of tetrahydrocannabivarin oil. The company is focused on operations in Oregon, California, and Nevada, United States.